Alkem Laboratories Limited

rs,

h November, 2023 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 34,402 million

umbai today. Key highlights of Q2FY24 financial performance • Total Revenue from Operations was ₹ 34,402 million, year-on-year growth of 11.7% o o India sales were ₹ 23,278 million, year-on-year growth of 5%

11.7%

inancial performance • Total Revenue from Operations was ₹ 34,402 million, year-on-year growth of 11.7% o o India sales were ₹ 23,278 million, year-on-year growth of 5% International sales were ₹ 1

₹ 23,278 million

evenue from Operations was ₹ 34,402 million, year-on-year growth of 11.7% o o India sales were ₹ 23,278 million, year-on-year growth of 5% International sales were ₹ 10,542 million, year-on-year growth of 27.1%

5%

on, year-on-year growth of 11.7% o o India sales were ₹ 23,278 million, year-on-year growth of 5% International sales were ₹ 10,542 million, year-on-year growth of 27.1% • Earnings before Interes

₹ 10,542 million

.7% o o India sales were ₹ 23,278 million, year-on-year growth of 5% International sales were ₹ 10,542 million, year-on-year growth of 27.1% • Earnings before Interest, Tax, Depreciation and Amortization (EBIT

27.1%

llion, year-on-year growth of 5% International sales were ₹ 10,542 million, year-on-year growth of 27.1% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 7,467 million, resu

₹ 7,467 million

n-year growth of 27.1% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 7,467 million, resulting in EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY • R&D e

21.7%

st, Tax, Depreciation and Amortization (EBITDA) was ₹ 7,467 million, resulting in EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY • R&D expenses for the quarter was ₹ 1,158 mi

14.7%

epreciation and Amortization (EBITDA) was ₹ 7,467 million, resulting in EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY • R&D expenses for the quarter was ₹ 1,158 million, or

64.5%

was ₹ 7,467 million, resulting in EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY • R&D expenses for the quarter was ₹ 1,158 million, or 3.4% of total revenue from operations

₹ 1,158 million

n of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY • R&D expenses for the quarter was ₹ 1,158 million, or 3.4% of total revenue from operations compared to ₹ 1,305 million in Q2FY23 at 4.2% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5999224&link SecurityString=2230867398 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in